OR5T2

Across TCGA pan-cancer cohorts, OR5T2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR5T2 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR5T2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5T2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, CESC, and LUSC are the cancer types where OR5T2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.326	0.780	<.001	30	view →
CESC	OS	Median	All	0.190	0.801	<.001	24	view →
LUSC	OS	Median	III,IV	0.307	0.695	.012	14	view →
STAD	OS	Median	IV	0.135	0.507	.007	12	view →
SKCM	OS	Median	All	0.987	0.862	.009	8	view →
UCEC	OS	Median	IV	0.346	0.764	<.001	6	view →
ESCA	DFS	Median	II,III,IV	0.185	0.532	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR5T2–LIHC (OS)

Open the LIHC breakdown →